July 2021—Qiagen and Inovio Pharmaceuticals announced an extension of their partnership with a new agreement to develop liquid-biopsy–based companion diagnostic products based on next-generation sequencing technology to complement Inovio’s therapies.
The initial project focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, Inovio’s immunotherapy to treat advanced cervical dysplasia associated with human papillomavirus. The assay will be developed for use on the Illumina NextSeq 550Dx platform, the first development based on a partnership that Qiagen and Illumina signed in October 2019.
VGX-3100 is Inovio’s late-stage DNA immunotherapy candidate. It is currently in two phase three trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with HPV-16 and HPV-18.
Inovio Pharmaceuticals, 267-440-4200
Qiagen, 800-426-8157